AstraZeneca has signed a drug discovery collaboration and licensing agreement with insitro to apply artificial intelligence ...
Fox Rothschild's Marc Wagner on why domestic manufacturing reduces drug shortage risk — and why FDA inspection efficiency is ...
MERGE's Pat McGloin on why pharma AI fails when strategy follows technology — and why the brilliant basics still have to come ...
The advantage comes from bringing all three into a disciplined decision process. Executives must recognize when experience ...
In today’s Pharmaceutical Executive Daily, Gilead and Vir Biotechnology enter a collaboration worth up to $1.87 billion to ...
FDA announced the Rare Disease Framework Initiative, a new effort to reimagine how drugs and biologics for rare diseases are developed and reviewed. The initiative was outlined in ...
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics ...
Experts warn prediction markets are exposing gaps in pharma vendor confidentiality agreements, Roche licenses Rona ...
Vir Biotechnology, entered a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN dual-masked T-cell engager development candidates target ...
Biotech startups face high failure rates, with nearly 90% failing and only 28% of first-time product launches exceeding forecasts. Early integration of commercialization strategies is crucial for ...
Fox Rothschild's Mark Wagner on why scaling drug production is so slow — overseas API sourcing, supplier qualification, and ...
Drug shortages remain a difficult to fix issue for the pharma industry and are an issue that can have devastating results.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results